ClinicalTrials.gg
TerminatedNCT06765226Updated Nov 17, 2026

Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps

An observational study in Heart Failure, sponsored by Abiomed Inc.. Terminated at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Abiomed Inc. (part of Johnson & Johnson) · Observational

How we know

Why this study was terminated
Following an interim review, the sponsor determined that the current study design would not adequately address the study objectives. The study was therefore terminated early, and findings will inform future research.
Updated Nov 17, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
27
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Heart Failure by Johnson & Johnson — 2 open to participants now, 5 under way, none of them phase 3. Heart Failure · Johnson & Johnson.

Started
2025
the only one that year
Observational
9 of 43
none open now
Registered
40th of 43
by date

Among the 43 studies in Heart Failure by Johnson & Johnson, this one is the only one that started in 2025, is one of 9 observational ones, and was the 40th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

2 of the 43 studies in Heart Failure by Johnson & Johnson are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Heart Failure by Johnson & Johnson, or all of them as a file.
02

Study summary

Analysis of cell and protein deposits on the Impella Heart Pump.

Read the detailed description

The Impella heart pump supports patients in cardiogenic shock for various reasons and has passed safety and biocompatibility evaluations. The planned investigation aims to further analyze cell and protein adhesion on these pumps and the effects of their prolonged use, especially in scenarios like bridge-to-transplant, recognizing preclinical testing limitations.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients treated with Impella CP or Impella 5.5 heart pump due to severe acute heart failure by any cause (e.g. cardiogenic shock in acute myocardial infarction, cardiac arrest, myocarditis or in relation to cardiac surgery).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Impella 5.5 therapy and duration of support for ≥ 25 days OR Patients with Impella CP therapy and duration of support for > 4 days

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
27 participants (actual)
Patient registry
No

Groups and cohorts

  • Impella CP

    Patients treated with Impella CP heart pump for more than 4 days due to severe acute heart failure by any cause

  • Impella 5.5

    Patients treated with Impella 5.5 heart pump for more than or equal to 25 days due to severe acute heart failure by any cause

06

What researchers measure

Primary outcomes

  1. Investigate deposits and biomaterial after use of pump

    investigate Impella CP after use regarding deposits and biomaterial

    Time frame: through study completion, at least 5 days

  2. Investigate deposits and biomaterial after use of pump

    investigate Impella 5.5 pumps after use regarding deposits and biomaterial

    Time frame: through study completion, at least 25 days

Secondary outcomes

  1. Relation deposits and biomaterial to clinical events

    By correlating patient data, such as medical history and Impella CP related blood parameters, with the findings from our pump analysis, potential connections between medication, diseases, comorbidities, and deposits on the pump can be identified.

    Time frame: through study completion, at least 5 days

  2. Relation deposits and biomaterial to clinical events

    By correlating patient data, such as medical history and Impella 5.5 related blood parameters, with the findings from our pump analysis, potential connections between medication, diseases, comorbidities, and deposits on the pump can be identified.

    Time frame: through study completion, at least 25 days

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided — No publication planned yet

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2025 to primary completion in Jun 2026, 9 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jul 2030 → Jun 2026 and completion Jan 2031 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 9, 2025
StartActual
Sep 21, 2025
Primary completionActual
Jun 25, 2026was Jul 2030
CompletionActual
Jun 25, 2026was Jan 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Following an interim review, the sponsor determined that the current study design would not adequately address the study objectives. The study was therefore terminated early, and findings will inform future research.
changed Nov 17, 2026
Sites
4 sites removed
Show 4 removed
  • Universitätsklinikum Düsseldorf · Düsseldorf, Germany
  • Herzzentrum Leipzig · Leipzig, Germany
  • Uniklinik Köln · Cologne, Germany
  • Westdeutsches Herz- und Gefäßzentrum Essen · Essen, Germany
Nov 17, 2026
Primary completion
Jul 31, 2030→Jun 25, 2026 (actual)
Nov 17, 2026
Study completion
Jan 31, 2031→Jun 25, 2026 (actual)
Nov 17, 2026
Enrollment
200 (estimated)→27 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Terminated
    Why stopped Following an interim review, the sponsor determined that the current study design would not adequately address the study objectives. The study was therefore terminated early, and findings will inform future research.
    4 sites removed
    Show 4 removed
    • Universitätsklinikum Düsseldorf · Düsseldorf, Germany
    • Herzzentrum Leipzig · Leipzig, Germany
    • Uniklinik Köln · Cologne, Germany
    • Westdeutsches Herz- und Gefäßzentrum Essen · Essen, Germany
    Primary completion Jul 31, 2030→Jun 25, 2026 (now actual)
    Study completion Jan 31, 2031→Jun 25, 2026 (now actual)
    Enrollment 200 (estimated)→27 (actual)
    + 2 other changes: responsible party and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06765226
Lead sponsor
Abiomed Inc.
Collaborators
Abiomed Europe GmbH
Responsible party
Sponsor
First posted
Jan 9, 2025
Start date
Sep 21, 2025
Primary completion
Jun 25, 2026
Completion
Jun 25, 2026
Last update
Nov 17, 2026

Study contacts

Pia Lanmüller, MD
principal investigator · Deutsches Herzzentrum der Charité

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion